Author:
Zhang Boxiang,Wang Huangzhen,Yang Litao,Zhang Yiwen,Wang Peili,Huang Guanghong,Zheng Jie,Ren Hong,Qin Sida
Funder
National Natural Science Foundation of China
Subject
Cell Biology,Pathology and Forensic Medicine
Reference31 articles.
1. Global cancer statistics, 2012;Torre;CA. Cancer J. Clin.,2015
2. Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations;Haaland;Thorac. Oncol.,2014
3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013
4. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial;Miller;Lancet Oncol.,2012
5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer;Liao;Eur. J. Nucl. Med. Mol. Imaging,2012
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献